Morgan Stanley initiated coverage of Novo Nordisk (NVO) with an Equal Weight rating and DKK 700 price target The firm says near-term U.S.
Novo Nordisk called out suppliers of compounded weight loss drugs following Hims & Hers’ controversial Super Bowl ad.
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback